Proton minibeam radiation therapy for treating metastases: A treatment plan study
Medical Physics · 2023-04 · 50 (4) · 2463-2473
DOI: 10.1002/mp.16203 ↗At a glance
Journal article in Medical Physics, published online on 2023-01-13. Written by Ramon Ortiz and 3 co-authors. Institution: Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, Orsay, France. Major MEDLINE topics: Proton Therapy, Glioma. Cited 25 times so far (Crossref); 57 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
Proton minibeam radiation therapy (pMBRT) is a new radiotherapy approach that has shown a significant increase in the therapeutic window in glioma‐bearing rats compared to conventional proton therapy. Such preclinical results encourage the preparation of clinical trials.
Purpose
In this study, the potential of pMBRT for treating clinical indications candidates for the first clinical trials (i.e., brain, lung, and liver metastases) was evaluated.
Methods
Four clinical cases, initially treated with stereotactic radiotherapy (SRT), were selected for this study. pMBRT, SRT, and conventional proton therapy (PT) dose distributions were compared by using three main criteria: (i) the tumor coverage, (ii) the mean dose to organs‐at‐risk, and (iii) the possible adverse effects in normal tissues by considering valley doses as the responsible for tissue sparing. pMBRT plans consisted of one fraction and one–two fields. Dose calculations were computed by means of Monte Carlo simulations. Results pMBRT treatments provide a similar or superior target coverage than SRT, even using fewer fields. pMBRT also significantly reduces the biologically effective dose (BED) to organs‐at‐risk. In addition, valley and mean doses to normal tissues remain below tolerance limits when treatments are delivered in a single fraction, contrary to PT treatments.
Conclusions
This work provides a first insight into the possibility of treating metastases with pMBRT. More favorable dose distributions and treatment delivery regimes may be expected from this new approach than SRT. The advantages of pMBRT would need to be confirmed by means of Phase I clinical trials.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, Orsay, France.
- Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, Orsay, France.
- Department of Radiation Oncology, Institut Curie, Paris, Saint Cloud, France.
- Centre de Protonthérapie d'Orsay, Radiation Oncology Department, Campus Universitaire, Institut Curie, PSL Research University, Orsay, France.
- Institut Curie, Campus Universitaire, PSL Research University, University Paris Saclay, INSERM LITO, Orsay, France.
Cite
APA
Ortiz, R., Belshi, R., De Marzi, L., & Prezado, Y. (2023). Proton minibeam radiation therapy for treating metastases: A treatment plan study. Medical Physics, 50(4), 2463-2473. https://doi.org/10.1002/mp.16203
Vancouver
Ortiz R, Belshi R, De Marzi L, Prezado Y. Proton minibeam radiation therapy for treating metastases: A treatment plan study. Medical Physics. 2023;50(4):2463-2473. doi:10.1002/mp.16203
BibTeX
@article{Ortiz2023,
author = {Ortiz, Ramon and Belshi, Rezart and De Marzi, Ludovic and Prezado, Yolanda},
title = {Proton minibeam radiation therapy for treating metastases: A treatment plan study},
journal = {Medical Physics},
year = {2023},
volume = {50},
number = {4},
pages = {2463--2473},
doi = {10.1002/mp.16203}
}
EUVIMED